Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study
Background: There has been significant improvement in treating metastatic non–small-cell lung cancer (mNSCLC) over the past 2 decades. The aim of this study is to describe the use of tyrosine kinase inhibitors (TKIs) in Qatar. This study focuses on the objective response rate (ORR) and reported adve...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-10-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/11795549241272490 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284385026179072 |
|---|---|
| author | Rawan Dawoud Harman Saman Kakil Rasul Farah Jibril Arwa Sahal Randa Al-Okka Yaser Mahfouz Nabil E. Omar Anas Hamad Reyad Mohsen Aladdin Kanbour Naim Battikh Prem Chandra Shereen Elazzazy |
| author_facet | Rawan Dawoud Harman Saman Kakil Rasul Farah Jibril Arwa Sahal Randa Al-Okka Yaser Mahfouz Nabil E. Omar Anas Hamad Reyad Mohsen Aladdin Kanbour Naim Battikh Prem Chandra Shereen Elazzazy |
| author_sort | Rawan Dawoud |
| collection | DOAJ |
| description | Background: There has been significant improvement in treating metastatic non–small-cell lung cancer (mNSCLC) over the past 2 decades. The aim of this study is to describe the use of tyrosine kinase inhibitors (TKIs) in Qatar. This study focuses on the objective response rate (ORR) and reported adverse drug events (ADEs) of TKIs used for the management of patients with mNSCLC. Methods: This is a descriptive retrospective cohort study. All non–small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations who received TKIs between 2015 and 2019 in Qatar were included. The TKIs used during this period include EGFR inhibitors such as afatinib, erlotinib, gefitinib, and osimertinib and ALK inhibitors such as alectinib and crizotinib. The response on each TKI was identified by reporting the ORR (as the sum of the complete response [CR] and the partial response [PR]), in addition stable disease (SD) and disease progression (DP) were reported. While ADEs were reported using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE). Results: A total of 63 patients were included, of which 36 cases (57.1%) expressed EGFR mutation, and 27 patients (42.9%) expressed ALK rearrangement. The ORR in EGFR inhibitors was as follows: osimertinib 40%, gefitinib 33%, afatinib 22%, and erlotinib 18%. However, the response to the ALK-targeted therapy was 43% with alectinib and 40% with crizotinib. A total of 112 ADEs were reported. They were distributed as 63.4% (71 of 112) with the anti-EGFR and 36.6% (41 of 112) ADEs with the ALK inhibitors. In the anti-EGFR group, the most common types of ADEs were dermatological toxicity 30%, whereas, in the anti-ALK group, gastrointestinal toxicity was the most common (29%). Conclusions: The EGFR-targeted and ALK-targeted therapies appear to have acceptable clinical response rate and safety profile in our population. Close and frequent monitoring of adverse events is advised to ensure a good quality of life and prevent serious complications. |
| format | Article |
| id | doaj-art-6f795f95bf0c4021a375317bfb5145ef |
| institution | OA Journals |
| issn | 1179-5549 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj-art-6f795f95bf0c4021a375317bfb5145ef2025-08-20T01:47:34ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492024-10-011810.1177/11795549241272490Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort StudyRawan Dawoud0Harman Saman1Kakil Rasul2Farah Jibril3Arwa Sahal4Randa Al-Okka5Yaser Mahfouz6Nabil E. Omar7Anas Hamad8Reyad Mohsen9Aladdin Kanbour10Naim Battikh11Prem Chandra12Shereen Elazzazy13Department of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Pulmonary Medicine, Hazm Mebaireek General Hospital, Hamad Medical Corporation, Doha, QatarDepartment of Medical Oncology, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Pharmacy, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarCollege of Pharmacy, QU Health, Qatar University, QatarDepartment of Medical Oncology, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Medical Oncology, The National Center of Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, QatarDepartment of Medical Research, Academic Health System, Hamad Medical Corporation, Doha, QatarCollege of Pharmacy, QU Health, Qatar University, QatarBackground: There has been significant improvement in treating metastatic non–small-cell lung cancer (mNSCLC) over the past 2 decades. The aim of this study is to describe the use of tyrosine kinase inhibitors (TKIs) in Qatar. This study focuses on the objective response rate (ORR) and reported adverse drug events (ADEs) of TKIs used for the management of patients with mNSCLC. Methods: This is a descriptive retrospective cohort study. All non–small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations who received TKIs between 2015 and 2019 in Qatar were included. The TKIs used during this period include EGFR inhibitors such as afatinib, erlotinib, gefitinib, and osimertinib and ALK inhibitors such as alectinib and crizotinib. The response on each TKI was identified by reporting the ORR (as the sum of the complete response [CR] and the partial response [PR]), in addition stable disease (SD) and disease progression (DP) were reported. While ADEs were reported using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE). Results: A total of 63 patients were included, of which 36 cases (57.1%) expressed EGFR mutation, and 27 patients (42.9%) expressed ALK rearrangement. The ORR in EGFR inhibitors was as follows: osimertinib 40%, gefitinib 33%, afatinib 22%, and erlotinib 18%. However, the response to the ALK-targeted therapy was 43% with alectinib and 40% with crizotinib. A total of 112 ADEs were reported. They were distributed as 63.4% (71 of 112) with the anti-EGFR and 36.6% (41 of 112) ADEs with the ALK inhibitors. In the anti-EGFR group, the most common types of ADEs were dermatological toxicity 30%, whereas, in the anti-ALK group, gastrointestinal toxicity was the most common (29%). Conclusions: The EGFR-targeted and ALK-targeted therapies appear to have acceptable clinical response rate and safety profile in our population. Close and frequent monitoring of adverse events is advised to ensure a good quality of life and prevent serious complications.https://doi.org/10.1177/11795549241272490 |
| spellingShingle | Rawan Dawoud Harman Saman Kakil Rasul Farah Jibril Arwa Sahal Randa Al-Okka Yaser Mahfouz Nabil E. Omar Anas Hamad Reyad Mohsen Aladdin Kanbour Naim Battikh Prem Chandra Shereen Elazzazy Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study Clinical Medicine Insights: Oncology |
| title | Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study |
| title_full | Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study |
| title_fullStr | Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study |
| title_full_unstemmed | Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study |
| title_short | Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study |
| title_sort | real world data presenting the descriptive analysis of the use of tyrosine kinase inhibitors tkis among metastatic non small cell lung cancer mnsclc patients in qatar a nationwide retrospective cohort study |
| url | https://doi.org/10.1177/11795549241272490 |
| work_keys_str_mv | AT rawandawoud realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT harmansaman realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT kakilrasul realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT farahjibril realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT arwasahal realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT randaalokka realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT yasermahfouz realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT nabileomar realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT anashamad realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT reyadmohsen realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT aladdinkanbour realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT naimbattikh realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT premchandra realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy AT shereenelazzazy realworlddatapresentingthedescriptiveanalysisoftheuseoftyrosinekinaseinhibitorstkisamongmetastaticnonsmallcelllungcancermnsclcpatientsinqataranationwideretrospectivecohortstudy |